Business context and reporting period
Surrozen, Inc. (Nasdaq: SRZN) filed this Form 8-K on October 2, 2026, reporting FDA clearance of its investigational new drug application for SZN-8141. This is an event filing, not a quarterly or annual financial report.
Key financial and operating information
- No revenue, profit, cash-flow, margin, debt, or liquidity figures are provided in the filing.
- The FDA clearance satisfies the second closing milestone under the company’s March 2025 two-tranche private placement. The second closing is expected to provide approximately $95.1 million in gross proceeds, before placement agent fees and other expenses, subject to the agreement’s terms, closing conditions, and completion of the closing.
- Surrozen expects the proceeds to support development of SZN-8141 and SZN-8143 and broader operating activities.
Program update and outlook
- SZN-8141 is a bifunctional Wnt agonist and vascular endothelial growth factor antagonist antibody being developed as an intravitreal treatment for diabetic macular edema (DME).
- Surrozen expects to dose the first patient in DUET, a Phase 1b/2a study in DME, in the fourth quarter of 2026; initial data are expected in the second half of 2027.
- The company also plans to develop SZN-8141 for neovascular age-related macular degeneration and is evaluating other retinal vascular diseases.
- The second private-placement closing is expected on or about October 20, 2026, subject to applicable conditions. After closing, the company expects to file a Form S-3 resale registration statement within 30 calendar days, as required by its registration rights agreement.
Material changes, risks, and contingencies
The reported development is FDA clearance of the IND, which allows SZN-8141 to advance into clinical development after the statutory 30-day review period. The clinical milestones and financing remain forward-looking expectations; the financing is conditional and proceeds would be reduced by fees and expenses. The filing provides no additional risk factors or quantified financial impact.
Important facts for investors to verify
- Whether the second private-placement closing occurs and the net proceeds after fees and expenses.
- Whether first-patient dosing in DUET begins in the fourth quarter of 2026 and initial data arrive in the second half of 2027.
- The terms and timing of the planned Form S-3 resale registration statement.